Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here's what to expect.
Pfizer beat analysts' revenue expectations last quarter, reporting revenues of $15.03 billion, up 2.6% year on year. It was a satisfactory quarter for the company, with a beat of analysts' EPS estimates but a miss of analysts' full-year EPS guidance estimates.
Is Pfizer a buy or sell going into earnings? Read our full analysis here, it's free for active Edge members .
This quarter, the market is expecting Pfizer's revenue to decline 4.8% year on year, improving from the 5.9% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Pfizer rarely misses Wall Street's revenue estimates.
Looking at Pfizer's peers in the branded pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 38.6%, beating analysts' expectations by 7.9%, and Supernus Pharmaceuticals reported revenues up 18.1%, topping estimates by 3.9%. Eli Lilly traded up 9.8% following the results while Supernus Pharmaceuticals's stock price was unchanged.
Read our full analysis of Eli Lilly's results here and Supernus Pharmaceuticals's results here .
There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 3.2% on average over the last month. Pfizer is up 11.1% during the same time and is heading into earnings with an average analyst price target of $29.26 (compared to the current share price of $30.45).
ALSO WORTH WATCHING: Nvidia's Quiet Partner.Nvidia's chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don't make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE .
